Navigation Links
Beckman Coulter Buys Out Royalty Obligation for Preeclampsia Markers

Initiates Clinical Trials Phase of Test Development Program

ORANGE COUNTY, Calif., Aug. 18 /PRNewswire-FirstCall/ -- Beckman Coulter, Inc. (NYSE: BEC) announced today that it signed an agreement to buy out its U.S. royalty obligation to Nephromics LLC, a Chestnut Hill, Mass.-based company focused on women's health. The license is for tests related to the detection, monitoring and risk assessment of preeclampsia, a leading cause of maternal death. In addition, Beckman Coulter obtained rights to acquire the worldwide diagnostics assets of Nephromics.


"Currently, there are no specific in vitro diagnostic tests for preeclampsia, even though the disease threatens the lives of thousands of women and their babies, and places a significant burden on healthcare systems worldwide," said Mike Whelan, vice president of Beckman Coulter's High Sensitivity Testing Business Group. "We expect that, once we complete our development program, these tests will help improve the outcomes of at-risk pregnancies. It is a powerful example of our commitment to provide clinical laboratories with the tools that improve patient health and reduce the cost of care. Our expectations for diagnostic testing related to maternal and fetal well-being leads us to believe that buying out our U.S. royalty obligation will create substantial value for our shareholders."

Beckman Coulter has initiated the clinical trial phase of its test development program. The new tests, expected to be useful as an aid in helping physicians diagnose preeclampsia, are being developed for use on the company's family of UniCel(R) DxI and Access(R) immunoassay systems, as well as UniCel DxCi chemistry-immunoassay work cells. The company plans to begin offering the tests by the end of 2009.

Preeclampsia, often characterized by hypertension and protein in the urine, occurs in up to 10 percent of all pregnancies in the developed world. During preeclampsia, the child is at risk from reduced placental blood circulation and function. The condition may result in premature birth, low birth weight and respiratory distress syndrome. For the mother, preeclampsia can mean seizures, brain, liver or other organ damage, even death. According to the World Health Organization, in the United States alone, preeclampsia is responsible for 18 percent of all maternal deaths, 80,000 premature births and numerous neonatal complications, and costs more than $7 billion in healthcare costs annually. With early detection, it may be possible to provide treatment to prevent serious complications.

About Beckman Coulter

Beckman Coulter, Inc., based in Orange County, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of supplies, test kits, service and operating-type lease payments, represents approximately 78 percent of the company's 2007 annual revenue of $2.76 billion. For more information, visit

Forward-looking Statements

This press release contains forward-looking statements, including statements regarding Beckman Coulter's development of a preeclampsia test. These statements are based on current expectations and assumptions. Actual results could differ materially from those anticipated by these forward-looking statements as a result of a number of factors, some of which may be beyond Beckman Coulter's control. Please see Beckman Coulter's reports filed with the Securities and Exchange Commission for information about the risks and uncertainties associated with Beckman Coulter's business. Beckman Coulter disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.


Cynthia Skoglund, Mary Luthy,

Investor Relations Corporate Communications

714.773.7620 714.773.7964

SOURCE Beckman Coulter, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Beckman Coulter Announces Licensing Agreements for Molecular Tests with National University of Ireland, Galway
2. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
3. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
4. Markers in Blood and Spinal Fluid, and a New Imaging Agent, Show Promise for Early Detection of Alzheimers
5. AviaraDx Confirms That Combination of Two Molecular Biomarkers Improves Prediction of Disease Recurrence in Early Stage Breast Cancer Patients
6. Biomarkers May Reduce the Need for Biopsies and Offer Personalized Care for Heart and Lung Transplant Patients
7. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
8. QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Womens Health Issues
9. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
10. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
11. CV Therapeutics Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36
Post Your Comments:
(Date:11/26/2015)... 2015 3D bioprinting market is ... a new report by Grand View Research Inc. Rising prevalence ... demands kidney transplantation is expected to boost the market growth, ... organ transplantation. --> 3D bioprinting market is ... a new report by Grand View Research Inc. Rising prevalence ...
(Date:11/26/2015)... 2015 ) ... "2016 Future Horizons and Growth Strategies in ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> ) has announced ... Horizons and Growth Strategies in the French ...
(Date:11/26/2015)... 2015 ) ... "2016 Future Horizons and Growth Strategies in ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> ) has announced ... Horizons and Growth Strategies in the German ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 27, 2015 , ... The rapid speed at which Americans ... more care is needed, especially with Alzheimer’s, dementia and other cognitive conditions becoming ... The forgotten part of this equation: 80 percent of medical care occurs in ...
(Date:11/27/2015)... ... November 27, 2015 , ... The ... of USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with a ... component is distributed nationally, through a vast social media strategy and across a ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, ... interesting show that delves into an array of issues that are presently affecting Americans. ... from open dialogue, this show is changing the subjects consumers focus on, one episode ...
(Date:11/27/2015)... ... ... Dr. Thomas Dunlap and Dr. Patrick Coleman , cardiologist ... Medicine at St., Joseph Health System’s Santa Rosa Memorial Hospital , co-hosted the ... ways and require time-critical intervention to avoid large area heart damage and progressive infections ...
(Date:11/26/2015)... Toronto, ON and Cambridge, ON (PRWEB) , ... ... ... announced today the availability of a real-time eReferral system for diagnostic imaging in ... CTs, ultrasounds, X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic ...
Breaking Medicine News(10 mins):